Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

CCR 20th Anniversary Commentary: Circulating Tumor Cells in Prostate Cancer.

Mehra N, Zafeiriou Z, Lorente D, Terstappen LW, de Bono JS.

Clin Cancer Res. 2015 Nov 15;21(22):4992-5. doi: 10.1158/1078-0432.CCR-14-3129.

2.

Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer.

Amato RJ, Melnikova V, Zhang Y, Liu W, Saxena S, Shah PK, Jensen BT, Torres KE, Davis DW.

Urology. 2013 Jun;81(6):1303-7. doi: 10.1016/j.urology.2012.10.041. Epub 2013 Apr 23.

PMID:
23622774
3.

Circulating tumor cells: a multifunctional biomarker.

Yap TA, Lorente D, Omlin A, Olmos D, de Bono JS.

Clin Cancer Res. 2014 May 15;20(10):2553-68. doi: 10.1158/1078-0432.CCR-13-2664. Review.

4.

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.

de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D.

Clin Cancer Res. 2008 Oct 1;14(19):6302-9. doi: 10.1158/1078-0432.CCR-08-0872. Erratum in: Clin Cancer Res. 2009 Feb 15;15(4):1506.

5.

Circulating tumor cells: clinical validity and utility.

Cabel L, Proudhon C, Gortais H, Loirat D, Coussy F, Pierga JY, Bidard FC.

Int J Clin Oncol. 2017 Jun;22(3):421-430. doi: 10.1007/s10147-017-1105-2. Epub 2017 Feb 25. Review.

PMID:
28238187
6.

Recent advances in circulating tumor cells and cell-free DNA in metastatic prostate cancer: a review.

Parimi S, Ko JJ.

Expert Rev Anticancer Ther. 2017 Oct;17(10):939-949. doi: 10.1080/14737140.2017.1359544. Epub 2017 Jul 31. Review.

PMID:
28737470
7.

Circulating tumor cells in localized prostate cancer: isolation, cultivation in vitro and relationship to T-stage and Gleason score.

Kolostova K, Broul M, Schraml J, Cegan M, Matkowski R, Fiutowski M, Bobek V.

Anticancer Res. 2014 Jul;34(7):3641-6.

PMID:
24982381
8.

The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis.

Xu L, Mao X, Guo T, Chan PY, Shaw G, Hines J, Stankiewicz E, Wang Y, Oliver RTD, Ahmad AS, Berney D, Shamash J, Lu YJ.

Clin Cancer Res. 2017 Sep 1;23(17):5112-5122. doi: 10.1158/1078-0432.CCR-16-3081. Epub 2017 Jun 14.

9.

Molecular characterization and clinical utility of circulating tumor cells in the treatment of prostate cancer.

Lorente D, Mateo J, de Bono JS.

Am Soc Clin Oncol Educ Book. 2014:e197-203. doi: 10.14694/EdBook_AM.2014.34.e197. Review.

10.

Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors.

Goodman OB Jr, Fink LM, Symanowski JT, Wong B, Grobaski B, Pomerantz D, Ma Y, Ward DC, Vogelzang NJ.

Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1904-13. doi: 10.1158/1055-9965.EPI-08-1173.

11.

Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer.

Meyer CP, Pantel K, Tennstedt P, Stroelin P, Schlomm T, Heinzer H, Riethdorf S, Steuber T.

Urol Oncol. 2016 May;34(5):235.e11-6. doi: 10.1016/j.urolonc.2015.12.003. Epub 2016 Jan 12.

PMID:
26795608
12.

Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer.

Paris PL, Kobayashi Y, Zhao Q, Zeng W, Sridharan S, Fan T, Adler HL, Yera ER, Zarrabi MH, Zucker S, Simko J, Chen WT, Rosenberg J.

Cancer Lett. 2009 May 18;277(2):164-73. doi: 10.1016/j.canlet.2008.12.007. Epub 2009 Jan 21.

PMID:
19162393
13.

Circulating tumor cells are transcriptionally similar to the primary tumor in a murine prostate model.

Helzer KT, Barnes HE, Day L, Harvey J, Billings PR, Forsyth A.

Cancer Res. 2009 Oct 1;69(19):7860-6. doi: 10.1158/0008-5472.CAN-09-0801. Epub 2009 Sep 29.

14.

EMT circulating tumor cells detected by cell-surface vimentin are associated with prostate cancer progression.

Satelli A, Batth I, Brownlee Z, Mitra A, Zhou S, Noh H, Rojas CR, Li H, Meng QH, Li S.

Oncotarget. 2017 Jul 25;8(30):49329-49337. doi: 10.18632/oncotarget.17632.

15.

mRNA-Seq of single prostate cancer circulating tumor cells reveals recapitulation of gene expression and pathways found in prostate cancer.

Cann GM, Gulzar ZG, Cooper S, Li R, Luo S, Tat M, Stuart S, Schroth G, Srinivas S, Ronaghi M, Brooks JD, Talasaz AH.

PLoS One. 2012;7(11):e49144. doi: 10.1371/journal.pone.0049144. Epub 2012 Nov 7.

16.

Circulating tumor cells in prostate cancer: a better predictor of survival than prostate specific antigen?

Hu B, Goldkorn A.

Expert Rev Anticancer Ther. 2014 Nov;14(11):1257-60. doi: 10.1586/14737140.2014.957190. Epub 2014 Sep 9.

PMID:
25199875
17.

Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.

Goodman OB Jr, Symanowski JT, Loudyi A, Fink LM, Ward DC, Vogelzang NJ.

Clin Genitourin Cancer. 2011 Sep;9(1):31-8. doi: 10.1016/j.clgc.2011.04.001. Epub 2011 Jun 25.

PMID:
21705286
18.

Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?

Ciccarese C, Montironi R, Fiorentino M, Martignoni G, Brunelli M, Iacovelli R, Lopez-Beltran A, Cheng L, Scarpelli M, Moch H, Tortora G, Massari F.

Curr Drug Metab. 2017;18(8):692-699. doi: 10.2174/1389200218666170518163549. Review.

PMID:
28524006
19.

Decreased adhesiveness, resistance to anoikis and suppression of GRP94 are integral to the survival of circulating tumor cells in prostate cancer.

Howard EW, Leung SC, Yuen HF, Chua CW, Lee DT, Chan KW, Wang X, Wong YC.

Clin Exp Metastasis. 2008;25(5):497-508. doi: 10.1007/s10585-008-9157-3. Epub 2008 Mar 14.

PMID:
18340425
20.

Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.

Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP 3rd, Datar RH, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M, Thompson IM Jr, Cote RJ, Vogelzang NJ.

J Clin Oncol. 2014 Apr 10;32(11):1136-42. doi: 10.1200/JCO.2013.51.7417. Epub 2014 Mar 10.

Supplemental Content

Support Center